LFCR vs LLY · rev $75.5M vs P/E 39, rev $22.97B
Lifecore Biomedical Inc. (LFCR) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Lifecore Biomedical Inc. (LFCR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David A. Ricks.
Latest reported LFCR revenue for 2025-12-31 was $75.5M. Net income was -$18.0M. Revenue was up 771.6% from 2025-06-30 to 2025-12-31. LFCR currently screens at market cap $207.1M.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
LFCR currently screens at market cap $207.1M. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the LFCR and LLY stock pages for the full models.
Not investment advice.